Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ipca Strikes Biosimilar Technology Transfer Amid Rising Ambitions In The Space

Indian Firm Counts Six MAbs In Its Pipeline, With Two Leading The Pack

Executive Summary

Ipca Laboratories underlined its commitment to successfully developing quality and affordable biosimilars meeting global standards as it penned a technology transfer agreement with a fellow Indian firm.

You may also be interested in...



Unichem Becomes A Part Of Ipca As Its Holding Moves Above 50%

Ipca Laboratories has completed an open offer for another slice of Unichem, following a recent deal to acquire a third of the company.

Emboldened In Court, Lupin Launches First US Oracea Generic At Risk

Lupin has shown its confidence in its legal position after introducing the first US generic version of Galderma’s rosacea treatment, Oracea, while the originator battles for injunctive relief.

Stada Tight-Lipped On Potential Sale Amid Reports Talks Are Underway

The rumor mill is heating up on Stada’s potential sale by its owners, Bain Capital and Cinven, after seven years at the helm.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel